Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1269-1274

  Silén, Åke ^a   Rizvi, Saiyid S H ^b   Letocha, Henry ^c   Lennernäs, Bo ^d   Wiklund, Bo ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b United Diagnostic Laboratories Inc   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e IDL Biotech AB   (Sweden)

Author keywords

Bladder cancer; Cytokeratin; Fragments; Ubc test; Urine

Indexed keywords

KERATIN; PEPTIDE FRAGMENT;

ADOLESCENT; ADULT; AGED; ANALYTICAL EQUIPMENT; ANEMIA; ARTICLE; BLADDER TUMOR; CANCER STAGING; CHILD; CLINICAL TRIAL; CYSTITIS; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; PATHOLOGY; PRESCHOOL CHILD; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURVIVAL; THYROID DISEASE; TRANSITIONAL CELL CARCINOMA; URINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CARCINOMA, TRANSITIONAL CELL; CHILD; CHILD, PRESCHOOL; CYSTITIS; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERLIPIDEMIAS; KERATINS; MALE; NEOPLASM STAGING; PEPTIDE FRAGMENTS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THYROID DISEASES; URINARY BLADDER NEOPLASMS;

EID: 0034320327     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1269     Document Type: Article

References (18)

1. TNM classification of malignant tumors: Third edition. Union International Contre le Cancer, Geneva, 1978.
2. Bergkvist M, Ljungkvist A and Moberger G: Classification of bladder tumors based on the cellular pattern: preliminary report of a clinical pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 130: 371-378, 1965.
3. Lieskovsky G, Ahlering T and Skinner DG: Diagnosis and staging of bladder cancer. In: Diagnosis and Management of Genitourinary Cancer. Skinner DG and Lieskovsky G (eds). WE Saunders Co., pp264-280, 1988.
4. Voges GE, Tauschke E, Stöckle M, Alken P and Hohenfellner R: Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol 142: 972-974, 1989.
5. Debus E, Moll R, Franke WW, Weber K and Osborn M: Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 114: 121-130, 1984.
6. Moll R, Achtstätter T, Becht E, Balcarova-Ständer J, Ittensohn M and Franke WW: Cytokeratins in normal and malignant transitional epithelium. Am J Pathol 132: 123-144, 1988.
7. Klein A, Zemer R, Buchumensky V, Klaper R and Nissenkorn I: Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer 82: 349-354, 1998.
8. Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982.
9. Achtstaetter T, Moll R, Moore B and Franke WW: Cytokeratin polypeptide pattern of different epithelia of the human male urogenital tract: immunofluorescence and gel electrophoretic studies. J Histochem Cytochem 33: 415-426, 1985.
10. Baker WC, White RD, Rossitto PV, Min BH and Cardiff RD: Quantitative analysis of keratin 18 in the urine of patients with bladder cancer. J Urol 40: 436-439, 1988.
11. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, Koiso K, Kobayashi M, Koyama A and Takahashi T: Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelia cancer. Eur Urol 31: 163-168, 1997.
12. Sarosdy MF, Hudson ML, Ellis W, Soloway S, deVere White R, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson D, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA and Brunelle SL: Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 50: 349-353, 1997.
13. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MG, Silberman SR and Butman BT: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for the detection and monitoring of bladder cancer. J Urol 158: 801-805, 1997.
14. Casetta G, Piana P, Cavallini A, Vottero M and Tizzani A: Urinary levels of tumour associated antigens (Ca 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities. Br J Urol 72: 60-64, 1993.
15. Yao WJ, Chang CJ, Chan SH, Chow NH, Cheng HL, Tzai TS and Lin SN: Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. Anticancer Res 15: 2819-2824, 1995.
16. Stieber P, Dienemann H, Hasholzner U, Fabricius PG, Schambeck C, Weinzierl M, Poley S, Samtlaben W, Hofmann K, Meier W, Untch M and Fateh-Moghadam A: Comparison of Cyfra 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 9: 82-88, 1994.
17. Dittadi R, Barioli P, Gion M, Mione R, Barichello M, Capitanio G, Cocco G, Cazzolato G, de Biasi F, Praturlon S, Antinozzi R and Gianneo E: Standardization of assay for cytokeratin-related tumor marker CYFRA 21-1 in urine samples. Clin Chem 42: 1634-1638, 1996.
18. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V and Soria F: An initial evaluation of the diagnostic performance of the new urinary bladder antigen cancer test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 161: 1110-1115, 1999.